Roche has reported a 7% increase in full-year 2024 sales at constant exchange rates (CER), reaching CHF 60.5bn ($66.9bn). The ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Roche said on Thursday it is targeting a continued increase in adjusted earnings per share (EPS) at a high single-digit percentage this year, helped by lower costs and growth from drugs such as eye ...

ZURICH, Jan 8 (Reuters) - Roche (ROG.S), opens new tab on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics (PSTX.O), opens new tab ...

Despite this looming danger, Roche’s leaders have, at least publicly, put on a brave face. They’ve reshaped the company’s structure and research priorities, and assured shareholders that new products ...

Swiss pharma giant Roche today released full-year 2024 financials, showing that group sales grew 7% at constant exchange ...

Shares in Swiss pharma giant Roche were more than 1% higher on Tuesday afternoon, following the announcement of positive ...

Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys for ...